Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > PPAR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.